The Latest Breaking News from Roche

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Merck is navigating a looming patent expiration for its blockbuster Keytruda. Now, Merck stock is trading at its highest point in decades.

While a recession in 2023 looks inevitable amid lingering macro headwinds, experts believe it to be mild. Moreover, amid high hopes for a Santa Claus rally, quality stocks Stellantis (STLA), Albertsons Companies (ACI), Poseida Therapeutics (PSTX), and Civeo (CVEO) could be ideal buys under $30 now. Keep reading….

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.